Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression.
Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression.
复制标题
艾曲波帕对急性髓系白血病细胞存活的抑制作用不依赖于 c-Mpl 表达。
DOI：
10.1038/leu.2012.310
复制
发表时间：
2013
期刊：
影响因子：
11.4
通讯作者：
Carroll,M
中科院分区：
文献类型：
--
作者：
Sugita,M;Kalota,A;Gewirtz,AM;Carroll,M
3 Szczepanski T，Orfao A，货车der Velden VH，San Miguel JF，货车Dongen JJ.白血病患者的微小残留病。柳叶刀肿瘤学2001; 2：409-417. 4 Flohr T，Schrauder A，Cazzaniga G，Panzer-Grumayer R，货车der Velden V，Fischer S等.在国际多中心试验AIEOP-BFM ALL 2000中使用免疫球蛋白和T细胞受体基因重排的实时定量PCR分析进行最小残留疾病定向风险分层，用于儿童急性淋巴细胞白血病。白血病2008; 22：771-782。5 Conter V，Bartram CR，Valsecchi MG，Schrauder A，Panzer-Grumayer R，Moricke A et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia：results in 3184 patients of the AIEOP-BFM ALL 2000 study.《血色2010》;一百一十五：3206-3214.6货车Dongen JJ，Seriu T，Panzer-Grumayer ER，Biondi A，Pongers-Willemse MJ，Corral L等.儿童急性淋巴细胞白血病微小残留病的预后价值。柳叶刀1998; 352：1731-1738. 7 Castor A，Nilsson L，Astrand-Grundstrom I，Buitenhuis M，Ramirez C，安德森K等.急性淋巴细胞白血病造血干细胞参与的独特模式. Nat Med 2005; 11：630-637. 8 Hong D，Gupta R，Ancliff P，Atzberger A，Brown J，Soneji S等.在TEL-AML 1相关儿童白血病中启动和癌症传播细胞。科学2008;三百一十九：336-339.9 le Viseur C，Hotfilder M，Bomken S，Wilson K，Rottgers S，Schrauder A et al. In childhood acute lymphoblastic leukemia，blasts at different stages of immunophenotypic maturation have stem cell properties.《癌细胞》2008年;十四日：47-58.10 Wilson K，Case M，Minto L，Bailey S，Bown N，Wendon J et al. Flow minimal residual disease monitoring of candidate leukemic stem cells defined by the immunophenotype，CD34 + CD38lowCD19 + in B-lineage children acute lymphoblastic leukemia. Haematologica 2010; 95：679-683. [11]李晓，李晓.儿童白血病：联邦德国德国的柏林-法兰克福-明斯特合作试验
3 Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol 2001; 2: 409–417. 4 Flohr T, Schrauder A, Cazzaniga G, Panzer-Grumayer R, van der Velden V, Fischer S et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771–782. 5 Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206–3214.6 van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731–1738. 7 Castor A, Nilsson L, Astrand-Grundstrom I, Buitenhuis M, Ramirez C, Anderson K et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 2005; 11: 630–637. 8 Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, Soneji S et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 2008; 319: 336–339.9 le Viseur C, Hotfilder M, Bomken S, Wilson K, Rottgers S, Schrauder A et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 2008; 14: 47–58.10 Wilson K, Case M, Minto L, Bailey S, Bown N, Jesson J et al. Flow minimal residual disease monitoring of candidate leukemic stem cells defined by the immunophenotype, CD34 þ CD38lowCD19 þ in B-lineage childhood acute lymphoblastic leukemia. Haematologica 2010; 95: 679–683. 11 Ritter J, Creutzig U, Reiter A, Riehm H, Schellong G. Childhood leukemia: cooperative Berlin–Frankfurt–Munster trials in the Federal Republic of Germany.